Global Prescription Pain Medications 麻豆原创 Research Report 2025

Publication ID:

PB503251215

Publication Date:

March 3, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global market for Prescription Pain Medications was valued at US$ 22370 million in the year 2024 and is projected to reach a revised size of US$ 30310 million by 2031, growing at a CAGR of 4.5% during the forecast period.
Prescription pain relievers are听drugs prescribed by a medical professional to reduce pain.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prescription Pain Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prescription Pain Medications.
The Prescription Pain Medications market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Prescription Pain Medications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prescription Pain Medications manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Pfizer
GSK
Grunenthal
Bayer
Sanofi
Eli Lilly
AstraZeneca
Endo
Merck
Depomed
Teva
Johnson & Johnson
Allergan
Segment by Type
Prescription NSAIDs
Opioids
Anti-epileptic Medicines
Antidepressants
Others
Segment by Application
Hospitals
Clinics
Drugstores
Others
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East and Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Prescription Pain Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Prescription Pain Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Prescription Pain Medications 麻豆原创 Overview
1.1 Product Definition
1.2 Prescription Pain Medications by Type
1.2.1 Global Prescription Pain Medications 麻豆原创 Value Comparison by Type (2024 VS 2031)
1.2.2 Prescription NSAIDs
1.2.3 Opioids
1.2.4 Anti-epileptic Medicines
1.2.5 Antidepressants
1.2.6 Others
1.3 Prescription Pain Medications by Application
1.3.1 Global Prescription Pain Medications 麻豆原创 Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Drugstores
1.3.5 Others
1.4 Global Prescription Pain Medications 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Prescription Pain Medications Revenue 2020-2031
1.4.2 Global Prescription Pain Medications Sales 2020-2031
1.4.3 Global Prescription Pain Medications 麻豆原创 Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Prescription Pain Medications 麻豆原创 Competition by Manufacturers
2.1 Global Prescription Pain Medications Sales 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Prescription Pain Medications Revenue 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Prescription Pain Medications Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Prescription Pain Medications, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Prescription Pain Medications, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Prescription Pain Medications, Product Type & Application
2.7 Global Key Manufacturers of Prescription Pain Medications, Date of Enter into This Industry
2.8 Global Prescription Pain Medications 麻豆原创 Competitive Situation and Trends
2.8.1 Global Prescription Pain Medications 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Prescription Pain Medications Players 麻豆原创 Share by Revenue
2.8.3 Global Prescription Pain Medications 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Prescription Pain Medications 麻豆原创 Scenario by Region
3.1 Global Prescription Pain Medications 麻豆原创 Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Prescription Pain Medications Sales by Region: 2020-2031
3.2.1 Global Prescription Pain Medications Sales by Region: 2020-2025
3.2.2 Global Prescription Pain Medications Sales by Region: 2026-2031
3.3 Global Prescription Pain Medications Revenue by Region: 2020-2031
3.3.1 Global Prescription Pain Medications Revenue by Region: 2020-2025
3.3.2 Global Prescription Pain Medications Revenue by Region: 2026-2031
3.4 North America Prescription Pain Medications 麻豆原创 Facts & Figures by Country
3.4.1 North America Prescription Pain Medications 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Prescription Pain Medications Sales by Country (2020-2031)
3.4.3 North America Prescription Pain Medications Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Prescription Pain Medications 麻豆原创 Facts & Figures by Country
3.5.1 Europe Prescription Pain Medications 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Prescription Pain Medications Sales by Country (2020-2031)
3.5.3 Europe Prescription Pain Medications Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Prescription Pain Medications 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Prescription Pain Medications 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Prescription Pain Medications Sales by Region (2020-2031)
3.6.3 Asia Pacific Prescription Pain Medications Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Prescription Pain Medications 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Prescription Pain Medications 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Prescription Pain Medications Sales by Country (2020-2031)
3.7.3 Latin America Prescription Pain Medications Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Prescription Pain Medications 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Prescription Pain Medications 麻豆原创 Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Prescription Pain Medications Sales by Country (2020-2031)
3.8.3 Middle East and Africa Prescription Pain Medications Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Prescription Pain Medications Sales by Type (2020-2031)
4.1.1 Global Prescription Pain Medications Sales by Type (2020-2025)
4.1.2 Global Prescription Pain Medications Sales by Type (2026-2031)
4.1.3 Global Prescription Pain Medications Sales 麻豆原创 Share by Type (2020-2031)
4.2 Global Prescription Pain Medications Revenue by Type (2020-2031)
4.2.1 Global Prescription Pain Medications Revenue by Type (2020-2025)
4.2.2 Global Prescription Pain Medications Revenue by Type (2026-2031)
4.2.3 Global Prescription Pain Medications Revenue 麻豆原创 Share by Type (2020-2031)
4.3 Global Prescription Pain Medications Price by Type (2020-2031)
5 Segment by Application
5.1 Global Prescription Pain Medications Sales by Application (2020-2031)
5.1.1 Global Prescription Pain Medications Sales by Application (2020-2025)
5.1.2 Global Prescription Pain Medications Sales by Application (2026-2031)
5.1.3 Global Prescription Pain Medications Sales 麻豆原创 Share by Application (2020-2031)
5.2 Global Prescription Pain Medications Revenue by Application (2020-2031)
5.2.1 Global Prescription Pain Medications Revenue by Application (2020-2025)
5.2.2 Global Prescription Pain Medications Revenue by Application (2026-2031)
5.2.3 Global Prescription Pain Medications Revenue 麻豆原创 Share by Application (2020-2031)
5.3 Global Prescription Pain Medications Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Prescription Pain Medications Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GSK Prescription Pain Medications Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Grunenthal
6.3.1 Grunenthal Company Information
6.3.2 Grunenthal Description and Business Overview
6.3.3 Grunenthal Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Grunenthal Prescription Pain Medications Product Portfolio
6.3.5 Grunenthal Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Company Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Bayer Prescription Pain Medications Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Company Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi Prescription Pain Medications Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Company Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Eli Lilly Prescription Pain Medications Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.7.4 AstraZeneca Prescription Pain Medications Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Endo
6.8.1 Endo Company Information
6.8.2 Endo Description and Business Overview
6.8.3 Endo Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Endo Prescription Pain Medications Product Portfolio
6.8.5 Endo Recent Developments/Updates
6.9 Merck
6.9.1 Merck Company Information
6.9.2 Merck Description and Business Overview
6.9.3 Merck Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Merck Prescription Pain Medications Product Portfolio
6.9.5 Merck Recent Developments/Updates
6.10 Depomed
6.10.1 Depomed Company Information
6.10.2 Depomed Description and Business Overview
6.10.3 Depomed Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Depomed Prescription Pain Medications Product Portfolio
6.10.5 Depomed Recent Developments/Updates
6.11 Teva
6.11.1 Teva Company Information
6.11.2 Teva Description and Business Overview
6.11.3 Teva Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Teva Prescription Pain Medications Product Portfolio
6.11.5 Teva Recent Developments/Updates
6.12 Johnson & Johnson
6.12.1 Johnson & Johnson Company Information
6.12.2 Johnson & Johnson Description and Business Overview
6.12.3 Johnson & Johnson Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Johnson & Johnson Prescription Pain Medications Product Portfolio
6.12.5 Johnson & Johnson Recent Developments/Updates
6.13 Allergan
6.13.1 Allergan Company Information
6.13.2 Allergan Description and Business Overview
6.13.3 Allergan Prescription Pain Medications Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Allergan Prescription Pain Medications Product Portfolio
6.13.5 Allergan Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Prescription Pain Medications Industry Chain Analysis
7.2 Prescription Pain Medications Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Prescription Pain Medications Production Mode & Process Analysis
7.4 Prescription Pain Medications Sales and 麻豆原创ing
7.4.1 Prescription Pain Medications Sales Channels
7.4.2 Prescription Pain Medications Distributors
7.5 Prescription Pain Medications Customer Analysis
8 Prescription Pain Medications 麻豆原创 Dynamics
8.1 Prescription Pain Medications Industry Trends
8.2 Prescription Pain Medications 麻豆原创 Drivers
8.3 Prescription Pain Medications 麻豆原创 Challenges
8.4 Prescription Pain Medications 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer
GSK
Grunenthal
Bayer
Sanofi
Eli Lilly
AstraZeneca
Endo
Merck
Depomed
Teva
Johnson & Johnson
Allergan

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.